deltatrials
Completed PHASE4 NCT00326963

BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.

A Multicenter, Open-label Study Evaluating the Safety and Efficacy of a New Protease Inhibitor (Darunavir) With Fuzeon® (Enfuvirtide) Plus Background Antiretroviral Regimen in HIV-1 Infected, Triple-class Treatment-experienced Patients

Sponsor: Hoffmann-La Roche

Conditions HIV Infections
Interventions Background ARVs PI enfuvirtide [Fuzeon]
Updated 7 times since 2017 Last updated: Jul 7, 2016 Started: Mar 31, 2006 Primary completion: Apr 30, 2007 Completion: May 31, 2007

Listed as NCT00326963, this PHASE4 trial focuses on HIV Infections and remains completed. Sponsored by Hoffmann-La Roche, it has been updated 7 times since 2006, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE4

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE4

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE4

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE4

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE4

    First recorded

Mar 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Hoffmann-La Roche
  • Trimeris
Data source: Hoffmann-La Roche

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States, Annandale, United States, Bakersfield, United States, Baltimore, United States, Beverly Hills, United States, Brisbane, Australia, Carlton, Australia, Dallas, United States, Decatur, United States, Fort Lauderdale, United States and 24 more location s